ATEC (ATEC) Q4 2025: EBITDA Margin Expands 400bps as Surgeon Adoption Drives Durable Growth
ATEC’s fourth quarter capped a year of double-digit growth and substantial margin expansion, underpinned by deepening surgeon adoption and operational leverage. The company’s spine-focused procedural ecosystem continues to gain share, with investments in technology and clinical differentiation fueling both top-line and profitability gains. 2026 guidance signals confidence in the sustainability of this growth engine and the scalability of its business model.
Summary
- Surgeon Adoption Accelerates: New user growth and higher utilization rates reinforce procedural ecosystem stickiness.
- Margin Structure Strengthens: Operating leverage from infrastructure and disciplined SG&A spend unlocks profitability at scale.
- 2026 Outlook Upgraded: Raised EBITDA guidance and continued investment in innovation position ATEC for further share gains.
Performance Analysis
ATEC delivered robust fourth quarter results, highlighted by 20% revenue growth and a 61% surge in adjusted EBITDA. Surgical revenue, the core of the business at over 85% of total, grew 21% year-over-year, powered by a 21% increase in procedural volumes and a 23% rise in net new surgeon users. EOS, the company’s imaging and informatics platform, contributed $23 million, up 14% year-over-year, and continues to drive incremental implant adoption post-installation.
Gross margin held steady at 70.5%, reflecting stable product mix and increasing asset efficiency. SG&A expense grew just 12% against a 20% revenue increase, enabling over 400 basis points of operating margin expansion. Operating leverage was further supported by improved variable selling expense and depreciation efficiencies. Free cash flow turned positive for the first full year, with $8 million generated in Q4 and $3 million for 2025, signaling a transition to self-funded growth.
- Volume-Driven Growth: U.S. same-store sales climbed 20%, and international mix modestly diluted average revenue per case.
- Cost Discipline: SG&A as a percentage of sales improved by 790 basis points for the year, with half the improvement from variable cost controls.
- Cash Generation Inflection: Free cash flow positive for the year, with a strong cash position and no revolver draw at year-end.
Annual adjusted EBITDA margin reached 12%, with a fourth quarter exit rate of 16%, reinforcing management’s conviction in further margin expansion in 2026.
Executive Commentary
"We are creating clinical distinction, mostly through proceduralization at this point. It is clearly compelling adoption. And we continue to expand and elevate our sales force... Our growth is sustainable because of our innovation and execution is aligned."
Pat Miles, Chairman and CEO
"We are delivering durable revenue growth, expanding profitability, and increasing cash generation, all at scale. The operating discipline across the organization is translating growth into sustainable financial strength."
Todd Koning, Chief Financial Officer
Strategic Positioning
1. Spine-Only Focus as Competitive Moat
ATEC’s 100% spine specialization creates a differentiated value proposition for surgeons, enabling the company to outpace broader medtech peers in both innovation velocity and clinical relevance. This focus underpins its leadership in lateral procedures and complex deformity solutions.
2. Procedural Ecosystem and Integrated Technology
The company’s ecosystem—anchored by procedural solutions, imaging (EOS Insight), and intraoperative platforms (Valence and SafeOp)—drives surgeon loyalty and utilization. EOS adoption accelerates implant pull-through, and new launches in 3D-printed implants and AI-driven planning tools further raise clinical switching costs.
3. Sales Channel Expansion and Talent Magnetism
ATEC’s disciplined sales hiring algorithm and reputation as a destination for top talent are fueling geographic and account penetration, with management citing strong demand from both surgeons and sales professionals. This supports both new user growth and deeper penetration in existing territories.
4. Operating Leverage and Self-Funded Growth
Structural investments in infrastructure and data integration are now delivering operating leverage, as evidenced by SG&A efficiencies and margin expansion. The transition to free cash flow generation enables continued investment in R&D and inventory without external financing.
5. Pipeline and Market Expansion
ATEC’s exclusive partnership with TheraAdaptive positions the company to enter the $700 million BMP (bone morphogenetic protein) market, with a next-generation product promising superior efficacy and safety. This long-term pipeline adds a new growth vector beyond the current procedural suite.
Key Considerations
ATEC’s quarter demonstrates a business model increasingly defined by operational discipline, clinical differentiation, and scalable growth. Investors should weigh:
Key Considerations:
- Surgeon Utilization Flywheel: Each new surgeon typically unlocks multi-year volume growth, with mid-teens utilization increases observed across cohorts.
- Seasonality Shift from Deformity Mix: Higher deformity case volumes in Q2 and Q3 flatten traditional Q4 surges, making quarterly growth less lumpy but potentially less visually dramatic.
- EOS Platform as Growth Catalyst: Low installed base penetration for EOS Insight leaves significant runway for imaging-driven implant adoption and data monetization.
- Margin Expansion Sustainability: Recent cost rationalization actions and infrastructure leverage are expected to drive nearly 400 basis points of further margin improvement in 2026.
Risks
Key risks include continued sensitivity to procedural mix, particularly as international and lower-ASP cases grow, and the need to maintain clinical leadership in a competitive spine landscape. Execution risk remains around sales hiring and new technology adoption, while regulatory and reimbursement changes could impact growth projections. Quarterly seasonality and the ramp phase of new launches may create near-term volatility.
Forward Outlook
For Q1 2026, ATEC expects:
- Revenue seasonality in line with 2025 patterns, with Q1 representing roughly 22% of full-year sales.
- Adjusted EBITDA margin to remain elevated in Q1, with slightly lower margins in subsequent quarters as investments ramp.
For full-year 2026, management raised guidance:
- Revenue of $890 million (17% growth), with surgical and EOS both contributing.
- Adjusted EBITDA of $134 million (15% margin), up from prior outlook.
- At least $20 million in free cash flow, reinforcing self-funded expansion.
Management emphasized continued investment in sales force expansion, product innovation, and technology integration as key to sustaining above-market growth.
- Focus on surgeon adoption and utilization ramp as primary growth levers.
- Ongoing margin expansion through cost and infrastructure leverage.
Takeaways
ATEC’s 2025 exit underscores the power of a spine-only, proceduralized model to deliver both growth and profitability at scale.
- Core Growth Engine: New surgeon adoption and deeper utilization are compounding, with EOS and procedural innovation extending the addressable market.
- Profitability Inflection: Margin expansion reflects structural cost control and the scalability of recent infrastructure investments, not just revenue growth.
- Watch for Pipeline Impact: TheraAdaptive BMP and continued EOS integration could unlock new revenue streams and further entrench ATEC’s competitive moat in spine.
Conclusion
ATEC’s Q4 2025 results validate its spine-focused, procedural ecosystem strategy, with accelerating surgeon adoption and operational discipline translating into durable, self-funded growth. With upgraded 2026 guidance and a robust innovation pipeline, ATEC remains positioned as a structural share gainer in the evolving spine market.
Industry Read-Through
ATEC’s performance and commentary highlight a broader industry shift toward procedural ecosystems and clinical integration in medtech. The success of EOS-driven implant pull-through and data-enabled planning tools signals the increasing importance of informatics and workflow integration for device companies. Margin expansion at scale, even as R&D and sales investments continue, raises the bar for operational discipline among spine and orthopedic peers. Competitors will need to address surgeon loyalty, technology stickiness, and the evolving expectations for end-to-end procedural support to maintain relevance as the market consolidates around integrated platforms.